The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Latest on alloCAR-T
Nina Shah, MD, of the University of California, San Francisco, CA, talks on the latest research on allogeneic CAR-T (alloCAR-T) therapies. Unlike autologous cell therapy, alloCAR-T products are derived from healthy donors, giving them the potential for ‘off-the-shelf’ use and hence solving many of the logistical challenges CAR-T currently imposes. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Nina Shah, MD, has received research funding from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar and Precision Biosciences; and has participated in an advisory role with GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides and CSL Behring.
